GSK halts the Phase III development of its herpes simplex virus (HSV) vaccine candidate, GSK3943104, after it failed to meet the primary efficacy objective in the Phase II trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.